UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8‑K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 8, 2017
Clearside Biomedical, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
Delaware | | 001-37783 | | 45-2437375 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer
Identification No.) |
1220 Old Alpharetta Road, Suite 300
Alpharetta, Georgia 30005
(Address of principal executive offices, including zip code)
(678) 270-3631
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On March 8, 2017, Daniel H. White, president and chief executive officer of Clearside Biomedical, Inc. (the “Company”), will present at the Cowen and Company 37th Annual Health Care Conference on, among other things, the Company’s product candidate pipeline. A copy of this presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| | |
| | |
Exhibit | | |
Number | | Exhibit Description |
99.1 | | Presentation titled “Clearside Biomedical - Cowen & Company 37th Annual Health Care Conference” dated March 8, 2017. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| | CLEARSIDE BIOMEDICAL, INC. |
| | |
| By: | /s/ Charles A. Deignan |
Date: March 8, 2017 | | Charles A. Deignan
Chief Financial Officer |
3
EXHIBIT INDEX
| | |
| | |
Exhibit | | |
Number | | Exhibit Description |
99.1 | | Presentation titled “Clearside Biomedical - Cowen & Company 37th Annual Health Care Conference” dated March 8, 2017. |
4
